This page was last updated on 22 July 2021.
The impact of COVID-19 on nuclear medicine supply
As you are all aware, COVID-19 transmission within nuclear medicine presents a risk to the security of supply. Any positive case within ANSTO's supply chain will likely see our facilities quarantined for a lengthy period of time.
To mitigate risk, we have altered staffing arrangements, similar to 2020’s COVID-19 operations. Many of you have already enquired as to when this would take place. As a result, you will notice the below impact to supply from 2 August.
- Gentech Generator capacity reduced by one-third per week: Customers will still be supplied activity; however, the day and frequency of delivery will change
- Iodine-131 order cut-off will be one day earlier
- Lutetium-177 supply will be as scheduled from 26 July
- Chromium-51 1 August calibration available, suspended from 1 September until further notice
Products below will be suspended until further notice:
- Gentech Generators
As you would appreciate, managing our facilities throughout a time of many unknowns is highly complex and there may be changes to these plans. So, moving forward, we'll provide weekly updates every Monday.
We are working with our internal partners to ensure they are prepared to operate in our nuclear medicine bubble.
To enhance the reliability of nuclear medicine supply and continued safe operations, over the coming months, ANSTO is conducting scheduled maintenance on its OPAL Reactor and Nuclear Medicine Processing and Distribution Facility.
- Nuclear medicine processing and distribution facility - 30 August-12 October
See how our operations adapt throughout scheduled maintenance.
Planning for more prolonged and frequent scheduled maintenance helps enable more reliable supply. The upcoming Nuclear Medicine Processing and Distribution Facility shutdown will run over six weeks to account for its postponement in March earlier this year, which allowed nuclear medicine supply in Australia when OPAL operations were temporarily interrupted.
ANSTO will work with our international partners to provide continuity of supply to the Australian nuclear medicine community. Support from the Australian Government means ANSTO will absorb all incremental costs associated with importing product and not pass these on to our customers.
Over the coming weeks, Customer Service will work with customers to plan orders well in advance and aim to minimise any impact on your business. See product availability here.
Thank you to the Nuclear Medicine Advisory Board and Working Group, with representation from RAINS, ANZSNM, AANMS, NSW Health, TGA and GMS, who have helped communicate the importance of this scheduled maintenance work to support the long term reliability of supply.